Palanisamy Arun P, Taber D J, Sutter A G, Nadig S N, Dowden J E, McGillicuddy J W, Baliga P K, Chavin K D
Division of Transplant Surgery, Department of Surgery, Medical University of South Carolina, 96 Jonathan Lucas Street, CSB 412, Charleston, SC, 29425, USA,
J Gastrointest Surg. 2015 Feb;19(2):282-9. doi: 10.1007/s11605-014-2675-1. Epub 2014 Oct 16.
In-hospital biliary complications (BCs) after liver transplantation (LT) are reported in up to 20 % of patients and contribute to poor outcomes and increased costs. Existing single-center outcome and cost analyses studies are limited in scope.
This is a cross-sectional analysis of national data involving 7,967 patients transplanted between 2011 and 2012 with the primary aim of determining the association between BCs and clinical outcomes and costs. Age, race, diagnosis, and severity of illness are associated with the development of BCs.
BCs develop in 14.6 % of LT recipients and have substantial implications for perioperative outcomes, including length of hospital and ICU stay (27.9 vs 19.6 mean days, p < 0.001 and 12.0 vs 8.3 mean days, p < 0.001, respectively), in-hospital morbidity (39 vs 27 %, p < 0.001), 30-day readmissions (14.8 vs 11.2 %, p < 0.001), and in-hospital mortality (5.8 vs 4.0 %, p < 0.001). BCs contributed to a mean increase in in-hospital costs of $36,212 (p < 0.001), due to increases in accommodations ($9,539, p < 0.001), surgical services ($3,988, p < 0.001), and pharmacy services ($8,445, p < 0.001).
BCs are a predominant etiology for in-hospital morbidity and mortality, while contributing significantly to the high cost of LT. Efforts should be focused on understanding salient and modifiable risk factors, while developing innovative strategies to reduce BCs.
肝移植(LT)后院内胆道并发症(BCs)在高达20%的患者中被报道,会导致不良预后并增加成本。现有的单中心结局和成本分析研究范围有限。
这是一项对国家数据的横断面分析,涉及2011年至2012年间接受移植的7967例患者,主要目的是确定BCs与临床结局及成本之间的关联。年龄、种族、诊断和疾病严重程度与BCs的发生有关。
14.6%的肝移植受者发生BCs,对围手术期结局有重大影响,包括住院时间和重症监护病房(ICU)停留时间(平均27.9天对19.6天,p<0.001;平均12.0天对8.3天,p<0.001)、院内发病率(39%对27%,p<0.001)、30天再入院率(14.8%对11.2%,p<0.001)和院内死亡率(5.8%对4.0%,p<0.001)。由于住宿费用增加(9539美元,p<0.001)、手术服务费用增加(3988美元,p<0.001)和药房服务费用增加(8445美元,p<0.001),BCs导致院内成本平均增加36212美元(p<0.001)。
BCs是院内发病和死亡的主要病因,同时对肝移植的高成本有重大影响。应致力于了解显著且可改变的风险因素,同时制定创新策略以减少BCs。